ClinicalTrials.Veeva

Menu
R

Royal North Shore Hospital | Renal Medicine - Renal Research Unit

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

gemcitabine
vinorelbine
cisplatin
5-fluorouracil
Cisplatin
Avelumab
67Cu
Dapagliflozin
Levofloxacin
Amoxicillin-clavulanate

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 73 total trials

A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO)

The purpose of this study is to assess the performance of imaging agent 64Cu-SARTATE in participants with known or suspected Gastroenteropancreatic (...

Active, not recruiting
Neuroendocrine Tumors
Drug: 64Cu-SARTATE

An open-label, ascending dose study for adult patients with Inclusion Body Myositis (IBM).

Active, not recruiting
Inclusion Body Myositis
Drug: ABC008

This is a study of pembrolizumab (MK-3475, KEYTRUDA®) in combination with lenvatinib (E7080) versus treatment of physician's choice (doxorubicin or p...

Active, not recruiting
Endometrial Neoplasms
Drug: Pembrolizumab
Drug: Doxorubicin

This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant...

Enrolling
Glioma
H3 K27M
Other: Placebo
Drug: ONC201

OPTIMISTmain is an investigator-initiated and conducted, international, multicentre, stepped wedge cluster randomized controlled trial comparing the...

Enrolling
Acute Ischemic Stroke Patients Receiving Reperfusion Therapy
Other: Low-intensity monitoring strategy
Other: Guideline recommended standard monitoring

The purpose of this study is to evaluate the safety, tolerability, and preliminary activity of SQ3370 in patients with advanced solid tumors.

Enrolling
Cancer
Drug: SQ3370

Rationale:Sodium glucose co transporter 2 (SGLT2) inhibitors are a relatively new class of agents, originally developed as oral antihyperglycemic dru...

Invitation-only
Kidney Failure
Death
Drug: Dapagliflozin 10 mg/day (oral)
Drug: Placebo

Trial sponsors

T
U
A
K
B
C
R
U
B
M

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems